C81.23
Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma, a type of cancer originating from a dysfunctional immune system. When this condition affects the intra-abdominal lymph nodes, it involves lymph nodes located within the abdominal cavity, such as those in the abdomen, pelvis, or near major blood vessels. This form of lymphoma can present with various symptoms due to the involvement of lymphatic tissue deep within the abdomen. Recognizing the signs, understanding its causes, and exploring treatment options are essential for effective management of this disease.
Causes & Symptoms
Clinical Causes: Genetic factors, potentially involving inherited predispositions Exposure to certain viruses, such as the Epstein-Barr virus (EBV) Immune system suppression or dysfunction Environmental factors, including exposure to certain chemicals or pesticides History of other lymphomas or immune-related disorders
Key Symptoms: Swollen and painless lymph nodes in the abdomen or pelvis Bloating or a feeling of fullness in the abdomen Unexplained weight loss Persistent fatigue and weakness Fever and night sweats Abdominal pain or discomfort Loss of appetite
Diagnostic & Treatment
Diagnosis Path: The diagnosis of mixed cellularity Hodgkin lymphoma typically involves multiple steps to confirm the presence of cancer and determine its extent. These may include:
Treatment Protocols: Treating mixed cellularity Hodgkin lymphoma in intra-abdominal lymph nodes usually involves a combination of therapies aimed at eradicating cancer cells and managing symptoms. The main treatment options include:
Clinical Advice & FAQs
Billing Guidance
Is C81.23 a billable ICD-10 code?
Yes, C81.23 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.23?
Clinical documentation must specify the nature of Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference